Neumora Therapeutics, Inc. (NASDAQ: NMRA) Q2 2025 Earnings | 08/07/2025

About this video

Neumora Therapeutics reported its second-quarter 2025 financial results, showing progress amid ongoing clinical development and pipeline expansion. The company posted a net loss of $52.7 million, an improvement from the $58.7 million loss in the same quarter a year ago. GAAP earnings per share (EPS) loss was $0.33, better than the forecasted loss of $0.45, reflecting operational efficiencies and cost management improvements. Research and development expenses declined to $38.7 million from $48.6 million in Q2 2024, driven by reduced stock-based compensation, personnel costs, and clinical trial expenses. General and administrative expenses held steady at $15.3 million. Neumora ended the quarter with a strong cash position of $217.6 million, expected to sustain operations into 2027. Strategic updates highlighted prioritizing obesity as the lead indication for NMRA-215, a brain-penetrant NLRP3 inhibitor, with data from diet-induced obesity models anticipated in 2025 and clinical progression planned for early 2026. The company also initiated a Phase 1 single and multiple ascending dose study for NMRA-861 targeting schizophrenia, expecting data in early 2026. Key upcoming catalysts include six clinical data readouts over the next 18 months, such as Phase 3 results for navacaprant in major depressive disorder and Phase 1b data for NMRA-511 in Alzheimer’s disease agitation. Management remains optimistic about advancing its pipeline, focusing resources on high-impact programs amid a catalyst-rich period, despite persistent net losses and market challenges. Risks include continued losses, clinical trial uncertainties, and competitive pressures. About Inside Ticker: Inside Ticker delivers timely, in-depth financial news and earnings analysis to empower investors with actionable insights on global companies across sectors. For comprehensive video analysis and real-time updates, visit https://www.insideticker.com/. #NeumoraTherapeutics #NMRA #Q22025 #Earnings #FinancialResults #NetLoss #EPS #R&D #CashPosition #ObesityTreatment #NLRP3Inhibitor #NMRA215 #NMRA861 #Navacaprant #MajorDepressiveDisorder #AlzheimersDisease #ClinicalTrials #Biopharmaceuticals #DrugDevelopment #Schizophrenia #Biotech #Pharmaceuticals #PipelineUpdates #Phase3Data #Phase1bData #BrainPenetrant #Innovation #Healthcare #BiotechInvesting #NASDAQ #InsideTicker #InvestorUpdates #ResearchAndDevelopment #ClinicalData #Therapeutics #LifeSciences